Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Itacitinib and ECP for First-Line Chronic GVHD
NCT04446182Phase 2Terminated
- Sponsor
- University of Utah
- Start
- Jan 2021
- Primary completion
- Mar 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of itacitinib in chronic graft-versus-host disease (cGVHD), sponsored by University of Utah. Started Jan 2021; status: terminated.
02
Drugs
itacitinib
03
Conditions
chronic graft-versus-host disease (cGVHD)
Beyond the preview
Go deeper on NCT04446182.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04446182.